Terns Pharmaceuticals Maintains Market Outperform Recommendation with 8.85% Downside Forecast

Citizens maintains a Market Outperform recommendation for Terns Pharmaceuticals (TERN) despite an analyst price forecast suggesting an 8.85% downside. The average one-year price target is $26.75/share, with a projected annual revenue of $0MM and a non-GAAP EPS of -1.95. There are 280 funds or institutions reporting positions in TERN, with Soleus Capital Management holding 8.02% ownership, and Vivo Capital holding 7.66% ownership. Fintel is a comprehensive investing research platform providing data on fundamentals, analyst reports, ownership data, and fund sentiment.